Effect of vitamin K2 ( MK-7 ) in treatment of diabetes

Effects of vitamin K2 (MK-7) oral supplementation on glycemic control and lipid profile in individuals with type 2 diabetes: A double-blind randomized clinical tial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190824044592N1

Enrollment

Registered

2019-12-22

Start date

2019-09-26

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: After 12 h fasting, blood samples were collected at the beginning and end of week 12. Patients of this group will intake 180 mcg vitamin k2 (MK-7) twice daily afte

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients who have diabetes since 1 year ago Glycated hemoglobin between 6.5 and 10 % Not intake of Warfarin, Phenytoin, Phenobarbital, Dicoumarol, Phenprocoumon drugs Patients treating with oral lowering blood glucose medications

Exclusion criteria

Exclusion criteria: Insulin injection Have chronic diseases such as heart, liver, kidney, cancer disease Having allergy to vitamin K Pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
Glycated hemoglobin A1c. Timepoint: Glycated hemoglobin A1c will be measured at the beginning of the study and after 90 days of starting supplementation. Method of measurement: Enzymatic colorimetric method.;Fasting Plasma Insulin. Timepoint: Fasting Plasma Insulin will be measured at the beginning of the study (before the intervention) and after 90 days of starting supplementation . Method of measurement: Enzyme-linked immunosorbent assay.;Fasting Plasma Glucose. Timepoint: Fasting Plasma Glucose will be measured at the beginning of the study (before the intervention) and after 90 days of starting supplementation. Method of measurement: Enzymatic colorimetric method.;Insulin resistance indexes. Timepoint: Insulin resistance indexes will be calculated at the beginning of the study (before the intervention) and after 90 days of starting supplementation . Method of measurement: Calculation.	—

Measure

Time frame

Glycated hemoglobin A1c. Timepoint: Glycated hemoglobin A1c will be measured at the beginning of the study and after 90 days of starting supplementation. Method of measurement: Enzymatic colorimetric method.;Fasting Plasma Insulin. Timepoint: Fasting Plasma Insulin will be measured at the beginning of the study (before the intervention) and after 90 days of starting supplementation . Method of measurement: Enzyme-linked immunosorbent assay.;Fasting Plasma Glucose. Timepoint: Fasting Plasma Glucose will be measured at the beginning of the study (before the intervention) and after 90 days of starting supplementation. Method of measurement: Enzymatic colorimetric method.;Insulin resistance indexes. Timepoint: Insulin resistance indexes will be calculated at the beginning of the study (before the intervention) and after 90 days of starting supplementation . Method of measurement: Calculation.

—

Secondary

Measure	Time frame
Serum Triglycerides. Timepoint: At the beginning and exactly at the end of intervention ( 90 days later ). Method of measurement: Enzymatic colorimetric method.;Serum cholesterol. Timepoint: At the beginning and exactly at the end of intervention ( 90 days later ). Method of measurement: Enzymatic colorimetric method.;High-density lipoprotein. Timepoint: At the beginning and exactly at the end of intervention ( 90 days later ). Method of measurement: Enzymatic colorimetric method.;Low-density lipoprotein. Timepoint: At the beginning and exactly at the end of intervention ( 90 days later ). Method of measurement: Enzymatic colorimetric method.	—

Measure

Time frame

Serum Triglycerides. Timepoint: At the beginning and exactly at the end of intervention ( 90 days later ). Method of measurement: Enzymatic colorimetric method.;Serum cholesterol. Timepoint: At the beginning and exactly at the end of intervention ( 90 days later ). Method of measurement: Enzymatic colorimetric method.;High-density lipoprotein. Timepoint: At the beginning and exactly at the end of intervention ( 90 days later ). Method of measurement: Enzymatic colorimetric method.;Low-density lipoprotein. Timepoint: At the beginning and exactly at the end of intervention ( 90 days later ). Method of measurement: Enzymatic colorimetric method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNazanin Moslehi

Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences

moslehinazanin@sbmu.ac.ir+98 21 2243 2500

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 23, 2026